Prime-Boost Immunization with Adenoviral and Modified Vaccinia Virus Ankara Vectors Enhances the Durability and Polyfunctionality of Protective Malaria CD8 + T-Cell Responses
Open Access
- 1 January 2010
- journal article
- research article
- Published by American Society for Microbiology in Infection and Immunity
- Vol. 78 (1) , 145-153
- https://doi.org/10.1128/iai.00740-09
Abstract
Protection against liver-stage malaria relies on the induction of high frequencies of antigen-specific CD8+ T cells. We have previously reported high protective levels against mouse malaria, albeit short-lived, by a single vaccination with adenoviral vectors coding for a liver-stage antigen (ME.TRAP). Here, we report that prime-boost regimens using modified vaccinia virus Ankara (MVA) and adenoviral vectors encoding ME.TRAP can enhance both short- and long-term sterile protection against malaria. Protection persisted for at least 6 months when simian adenoviruses AdCh63 and AdC9 were used as priming vectors. Kinetic analysis showed that the MVA boost made the adenoviral-primed T cells markedly more polyfunctional, with the number of gamma interferon (INF-γ), tumor necrosis factor alpha (TNF-α), and interleukin-2 (IL-2) triple-positive and INF-γ and TNF-α double-positive cells increasing over time, while INF-γ single-positive cells declined with time. However, IFN-γ production prevailed as the main immune correlate of protection, while neither an increase of polyfunctionality nor a high integrated mean fluorescence intensity (iMFI) correlated with protection. These data highlight the ability of optimized viral vector prime-boost regimens to generate more protective and sustained CD8+ T-cell responses, and our results encourage a more nuanced assessment of the importance of inducing polyfunctional CD8+ T cells by vaccination.Keywords
This publication has 26 references indexed in Scilit:
- HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cellsBlood, 2006
- Anti-CD25 Antibody Enhancement of Vaccine-Induced Immunogenicity: Increased Durable Cellular Immunity with Reduced ImmunodominanceThe Journal of Immunology, 2005
- Synergistic DNA–MVA prime-boost vaccination regimes for malaria and tuberculosisVaccine, 2005
- Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus AnkaraProceedings of the National Academy of Sciences, 2005
- Human Immunodeficiency Virus Type 1-Specific Immune Responses in Primates upon Sequential Immunization with Adenoviral Vaccine Carriers of Human and Simian SerotypesJournal of Virology, 2004
- Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus AnkaraNature Medicine, 1998
- A protein particle vaccine containing multiple malaria epitopesNature Biotechnology, 1997
- Protection against malaria by immunization with plasmid DNA encoding circumsporozoite protein.Proceedings of the National Academy of Sciences, 1994
- Immunization of man against sporozite-induced falciparum malariaThe Lancet Healthy Longevity, 1973
- Protective Immunity produced by the Injection of X-irradiated Sporozoites of Plasmodium bergheiNature, 1967